Body
ANN ARBOR, Mich. -- Frosted cupcakes, sprinkled donuts and chocolate chip cookies -- all on the list of foods that pediatrician Megan Pesch suddenly found difficult to avoid.
Not at the bakery or grocery store, but on children's clothing.
The mother of three daughters couldn't help but notice that food graphics had become fashionable -- from sleep sacks and pajamas adorned with pink and purple donut patterns to T-shirts decorated with ice cream cones and cutesy sayings about being "sweet."
An in-home exercise program reduced subsequent falls in high-risk seniors by 36 per cent, according the results of a 12-month clinical trial published today in the Journal of the American Medical Association.
The study, conducted by UBC faculty of medicine researchers in partnership with the clinical team at the Falls Prevention Clinic at Vancouver General Hospital, found a reduction in fall rate and a small improvement in cognitive function in seniors who received strength and balance training through the clinical trial.
Results of a Phase II clinical trial conducted at The University of Texas MD Anderson Cancer Center revealed that combination targeted therapy, consisting of rituximab, lenalidomide and ibrutinib (RLI), had an 84.6 percent overall response rate (ORR) and 38.5 percent complete response rate (CRR) when given prior to any chemotherapy for newly diagnosed patients with a specific type of diffuse large b-cell lymphoma (DLBCL).
Scientists at VCU Massey Cancer Center have identified key biological pathways that regulate the spread of tumor cells to vital organs. These findings may have a significant influence on the development of new therapies that slow or prevent breast cancer metastasis.
Metastasis refers to the spread of cancer cells to other organs, and the likelihood of curing cancer is significantly reduced once the disease has spread. Nearly all breast cancer deaths are caused by metastasis within vital organs.
HANOVER, N.H. - June 4, 2019 - A research team at Dartmouth College has developed a new strategy for drug discovery and development that can be used to produce targeted therapies against diseases such as cancer and neurodegeneration, according to a study published in Nature Communications.
It is hoped that the process will also be useful in the large-scale production of new pharmaceuticals.
Oregon is considering a bill to implement paid family leave, House Bill 2005, following in the footsteps of Washington, which approved a similar policy in 2017.
Oregon Health and Science University-Portland State University School of Public Health researchers concluded that it's not just approving paid family leave that's important for employees -- how that policy is implemented to make it equitable for all employees is just as critical.
HOUSTON - (June 3, 2019) - Help for patients with sickle cell disease may soon come from gene editing to fix the mutation that causes the disease and boost the patient's own protective fetal hemoglobin.
New research shows that using CRISPR-Cas9 and a corrective short DNA template to repair the sickle cell mutation in a patient's hematopoietic stem cells (HSCs) could be efficient and safe.
CHICAGO - Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response (MPR) rate of 33 percent of treated patients with early-stage, resectable non-small cell lung cancers, meaning these patients had less than or equal to 10 percent viable tumor remaining at surgery. With these results, the combination immunotherapy met the pre-specified trial efficacy endpoint of the phase II NEOSTAR trial conducted by researchers at The University of Texas MD Anderson Cancer Center.
A UCLA-led study has found that using a drug called ribociclib in combination with a common hormone therapy may help premenopausal women with the most common type of breast cancer live longer than if they only receive the hormone therapy.
Ribociclib is considered a cyclin-dependent kinase inhibitor that works by blocking the activity of proteins called cyclin-dependent kinase 4/6 enzymes, which promote cell division and cancer growth.
Treatment with the drug olaparib significantly reduced the risk of disease progression or death from metastatic pancreatic cancer, according to findings from the recently completed, international, phase-III POLO (Pancreas cancer OLaparib Ongoing) trial.
Olaparib (trade name LYNPARZA, jointly developed and commercialized by AstraZeneca and Merck) is a PARP inhibitor. It targets cancer cells that have a defect in DNA damage repair.
Treatment with dabrafenib and trametinib, a drug combination designed to target cancers that harbor certain BRAF gene mutations, was effective in a trial of 35 patients representing 17 distinct tumor types. The single-arm phase two study (Arm H), met its primary endpoint. The results will be orally presented on Monday, June 3rd at the annual meeting of the American Society of Clinical Oncology (Meeting Abstract 3002). Arm H is one of multiple treatment arms in the NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131) trial.
Results from the phase III NRG Oncology clinical trial GOG 0261 comparing paclitaxel plus carboplatin (PC) to paclitaxel plus ifosfamide (PI) in women with stage I-IV, recurrent carcinosarcoma of the uterus or ovary, indicate that the PC combination treatment should be considered a standard of care for this patient population. The study concludes that among uterine cancer patients treatment with PC was not inferior to PI based on the primary objective overall survival (OS), and PC was associated with longer progression-free survival (PFS) outcomes when compared with PI.
DALLAS, June 3, 2019 -- Effective antiretroviral therapy has changed the human immunodeficiency virus (HIV) from a progressive, fatal disease to a chronic, manageable condition that is associated with higher rates of heart attacks, strokes, heart failure, sudden cardiac deaths, and other diseases compared to people without HIV, according to a new scientific statement from the American Heart Association published in the Association journal Circulation.
Research led by faculty at Children's National published online June 3, 2019, in Nature Communications shows that the sudden appearance of symptoms in limb-girdle muscular dystrophy type 2 (LGMD2B) is a result of impaired communication between different cell types that facilitate repair in healthy muscle. Of particular interest are the fibro/adipogenic precursors (FAPs), cells that typically play a helpful role in regenerating muscle after injury by removing debris and enhancing the fusion of muscle cells into new myofibers.
A consortium of scientists from the Medical Imaging Center (University Medical Center Groningen), Van 't Hoff Institute for Molecular Sciences (University of Amsterdam), Palacky University in Olomouc, the University of Nantes, Stratingh Institute for Chemistry (University of Groningen) and the European Laboratory for Non-Linear Spectroscopy in Florence have developed an entirely new class of molecular photoswitches that meet many of the 'holy grail' requirements so far thought to be impossible to achieve. The results have been published in Nature Communications on 3 June.